<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040922</url>
  </required_header>
  <id_info>
    <org_study_id>13091</org_study_id>
    <secondary_id>13/EM/0310</secondary_id>
    <nct_id>NCT02040922</nct_id>
  </id_info>
  <brief_title>Campylobacter Enteritis and Post-Infective Bowel Dysfunction (PI-BD): Role of Antibiotics and Microbiota</brief_title>
  <acronym>CERAMIC</acronym>
  <official_title>An Observational Study of the Role of Antibiotics, Inflammation and Changes in Microbiota in the Development of Post-infective Bowel Dysfunction Following Infection With Campylobacter Jejuni or Coli</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Health, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal research objective is to determine the impact of antibiotic use on the risk of&#xD;
      developing long term bowel symptoms after infection with the germ Campylobacter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary research objectives are:&#xD;
&#xD;
        -  To investigate how the particular strain of the Campylobacter germ that causes the&#xD;
           infection, and the strength of the immune response that it stimulates in the bowel,&#xD;
           affect the risk of long term bowel symptoms.&#xD;
&#xD;
        -  To explore what changes occur after Campylobacter infection in the bacteria that usually&#xD;
           live in the large bowel (microbiota) and the chemicals that they produce (short-chain&#xD;
           fatty acids) when they digest nutrients. We will look for differences between people who&#xD;
           recover fully and people who have long term bowel symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Yes/ no: Post-Infective bowel dysfunction (PI-BD)</measure>
    <time_frame>12 weeks after microbiological diagnosis of infection</time_frame>
    <description>This will be defined by response to the question &quot;have your bowels returned to normal since your Campylobacter infection?&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yes/ No: Post-Infective irritable bowel syndrome (PI-IBS)</measure>
    <time_frame>12 weeks after microbiological diagnosis of infection</time_frame>
    <description>Symptoms meeting Rome III criteria for Irritable Bowel Syndrome (other than 6 month duration)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Campylobacter Infections</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Post-Campylobacter</arm_group_label>
    <description>Adults with symptoms of intestinal infection who submit a stool sample from which Campylobacter jejuni or coli is cultured</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool (Faeces) Whole Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults in the Nottinghamshire area with no previous history of gastrointestinal disorder or&#xD;
        surgical resection. Those who submit a stoo lsample from which Campylobacter spp. is&#xD;
        cultured will be invited to take part.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
          -  Clinical syndrome suggestive of intestinal infection, including symptoms such as new&#xD;
             onset of abdominal pain, vomiting, diarrhoea, blood in stools, fever&#xD;
&#xD;
          -  Submission of stool sample to Nottingham University Hospitals Microbiology Laboratory&#xD;
             for investigation of these symptoms&#xD;
&#xD;
          -  Campylobacter sp. cultured by selective media (standard clinical practice) from this&#xD;
             stool sample&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy declared by the candidate&#xD;
&#xD;
          -  History declared by the candidate of pre-existing gastrointestinal disorder, including&#xD;
             but not limited to:&#xD;
&#xD;
               -  Inflammatory Bowel Disease&#xD;
&#xD;
               -  Coeliac Disease&#xD;
&#xD;
               -  Pancreatitis&#xD;
&#xD;
               -  Gallstone disease (biliary colic, cholecystitis)&#xD;
&#xD;
               -  Diverticulitis&#xD;
&#xD;
               -  Cancer of the gastrointestinal tract&#xD;
&#xD;
               -  Irritable Bowel Syndrome&#xD;
&#xD;
          -  Reported history of previous resection of any part of the gastrointestinal tract other&#xD;
             than appendix or gallbladder&#xD;
&#xD;
          -  Intestinal stoma&#xD;
&#xD;
          -  Habitual use of opiate analgesics likely to alter bowel function e.g. morphine&#xD;
&#xD;
          -  Use of antibiotics in the preceding four weeks other than for treatment of index&#xD;
             infection.&#xD;
&#xD;
          -  Use of purgative products/ high dose laxatives for bowel preparation in the four weeks&#xD;
             prior to index infection.&#xD;
&#xD;
          -  Any condition where the candidate is likely to require a course of antibiotics in the&#xD;
             next 3 months e.g. severe chronic respiratory disease, recurrent urinary tract&#xD;
             infection, lower limb ulceration&#xD;
&#xD;
          -  Inability to complete the symptom questionnaires e.g. cognitive dysfunction limiting&#xD;
             memory and understanding&#xD;
&#xD;
          -  Declared participation in any medical trials in the past 3 months&#xD;
&#xD;
          -  Anyone who in the opinion of the investigator is unlikely to be able to comply with&#xD;
             the protocol e.g. cognitive dysfunction, chaotic lifestyle related to substance abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin C Spiller, MSc MD FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giles AD Major, BM BCh MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mathew Diggle, MSc PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nottingham University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Puleston, MBBS PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miranda Lomer, PhD RD</last_name>
    <role>Study Director</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nottingham</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.nddcbru.org.uk</url>
    <description>Departmental website</description>
  </link>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotics</keyword>
  <keyword>Campylobacter</keyword>
  <keyword>Diarrhoea</keyword>
  <keyword>Enteritis</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Calprotectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Campylobacter Infections</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

